LINDA ABAD: Open Payments
NPI 1063928240 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$923 in 10 payments from 8 companies in 2025. Trend: 2023 $190 · 2024 $360 · 2025 $923
Food & beverage: $923
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $261 |
| ABIOMED | 1 | $126 |
| Alcresta Therapeutics, Inc. | 1 | $124 |
| Actelion Pharmaceuticals US, Inc. | 1 | $124 |
| Fresenius Kabi USA, LLC | 1 | $123 |
| Mallinckrodt Hospital Products Inc. | 1 | $108 |
| Merck Sharp & Dohme LLC | 1 | $33 |
| Alexion Pharmaceuticals, Inc. | 1 | $25 |
Products named: EMBLAVEO, RELIZORB, UPTRAVI, Smoflipid, TERLIVAZ, ZERBAXA, ULTOMIRIS, AVYCAZ.
Industry payments across TX — which companies pay providers there.
